Trial Profile
An Open-label, Uncontrolled Phase II-study to Investigate Pharmacokinetics, Safety and Biomarkers of Effectiveness of NeuroSTAT (Ciclosporin) in Patients With Severe Traumatic Brain Injury (TBI)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary)
- Indications Traumatic brain injuries
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms CHIC
- Sponsors Abliva
- 04 Oct 2018 According to a NeuroVive Pharmaceutical media release, biomarker analyses using samples from this study patients has been completed.
- 04 Oct 2018 Results of biomarker analyses using samples from this study patients, presented in a NeuroVive Pharmaceutical media release.
- 15 Feb 2018 According to a NeuroVive Pharmaceuticals media release, the company expects presentation of complete results from this trial in 2018.